TotalMarketCap

Tarsus Pharmaceuticals

TARSNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.332 B

$67.59 -2.15%

Close of 6 Nov 2026

As of 6 Nov 2026, Tarsus Pharmaceuticals (TARS) has a market capitalization of $3.33B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$451.4M

#1944 by revenue

Earnings

-$66.0M

Loss-making

Shares outstanding

49,305,552

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #25Relay TherapeuticsRLAY$3.76B
  2. #26Iovance BiotherapeuticsIOVA$3.49B
  3. #27Tarsus PharmaceuticalsTARS$3.33B
  4. #28Denali TherapeuticsDNLI$3.16B
  5. #29Adma BiologicsADMA$2.94B

What if Tarsus Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $28.2T

$572,691.57

Per share 8,474× higher

Bitcoin $1.53T

$30,987.34

Per share 458× higher

Apple $5.02T

$101,728.56

Per share 1,505× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Tarsus Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.